ArticleMikrochimica acta2026
Methylene blue-modified hexagonal boron nitride nanostructured immunosensor for early detection of HPV16 E6 oncoprotein.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Human papillomavirus type 16 E6 oncoprotein is a clinically significant biomarker for cervical cancer because its persistent expression drives malignant transformation. To address the need for ultrasensitive detection of oncogenic HPV16 E6 protein, we engineered an electrochemical immunosensor based on methylene blue-functionalized hexagonal boron nitride (BN-MB) nanosheets deposited on screen-printed carbon electrodes. In this architectonic design, exfoliated h-BN provides a high-surface-area support, while the π-π-stacked cationic dye methylene blue acts as an internal redox mediator, converting intrinsically insulating h-BN into an electroactive matrix. Protein G was immobilized to orient monoclonal anti-E6 antibodies in a tail-on configuration, thereby enhancing antigen accessibility. Under optimized conditions, square-wave voltammetry showed a wide linear range from 1 fg mL⁻¹ to 1 ng mL⁻¹, with an ultralow limit of detection of 0.80 fg mL⁻¹ using the 3σ/m method and a limit of quantification of 2.67 fg mL⁻¹. Zeta potential measurements and FTIR analysis confirmed strong electrostatic and π-π interactions between MB and h-BN, while MB loading was determined by UV-vis absorbance. The immunosensor exhibited excellent selectivity against a panel of interferents, including E7 oncoprotein, SCCA, CEA, and CA-125, high stability with approximately 87% signal retention after 30 days at 4 °C, and good reproducibility with a relative standard deviation of 3.20%. Analysis of E6-spiked human serum samples and samples collected from seven HPV-positive patients showed generally good agreement with commercial ELISA, while some variability was observed among individual clinical samples. Overall, the BN-MB immunosensor demonstrates an innovative material platform for point-of-care screening of cervical cancer biomarkers.
Indexed as
Identifiers
42631732What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.